Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...
Evotec SE回应媒体猜测
德国汉堡 - 专注于药物发现和开发的制药公司Evotec SE今天向美国证券交易委员会提交了一份临时公告，回应了最近的媒体猜测。这家在法兰克福证券交易所以EVO为股票代码上市的公司，对有关其业务运营的报道作出了澄清。 在公告中，Evotec的首席执行官Christian Wojczewski表示："我们经常评估潜在的战略机会以提升股东价值，并将继续这样做。"Wojczewski强调，虽然公司愿意探 ...
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .
腾讯网6 天
传私募公司Triton拟收购德国药物开发商Evotec(EVO.US)
智通财经APP获悉，据知情人士透露，私募股权公司Triton Partners正在考虑收购德国生物科技公司Evotec (EVO.US)。此前，这家公司已成为Evotec的最大股东之一。
uk.investing.com on MSN2 天
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...
FierceBiotech2 天
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...
ENDPOINTS NEWS2 天
Evotec gains on Halozyme's takeover pro­pos­al
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...
哈洛齐梅提议以20亿欧元收购Evotec
圣地亚哥 - Halozyme Therapeutics, Inc. (NASDAQ: HALO)提出了一项非约束性提议,以每股11.00欧元的现金价格收购Evotec SE (NASDAQ: EVO),这将使Evotec的股权价值约为20亿欧元。这一报价相对于2024年10月15日Triton Partners开始累积股份之前的Evotec股价有显著溢价。 此次收购将把Halozyme的药物输送 ...
MarketWatch2 天
Evotec Shares Surge on $2.11 Billion Buyout Offer
Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...
阿思達克財經網6 天
传私募公司Triton拟收购德国药物开发商Evotec(EVO.US)
智通财经APP获悉，据知情人士透露，私募股权公司Triton Partners正在考虑收购德国生物科技公司Evotec(EVO.US)。此前，这家公司已成为Evotec的最大股东之一。
Evotec soars on Triton's near 10% stake, report it weighs buyout bid
Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio. Halozyme ...